AstraZeneca said on Friday its and Daiichi Sankyo’s cancer drug Enhertu was recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).

The recommendation is based on the mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.

EU INITIATES ASSESSMENT OF HUMAN AND LABOR RIGHTS IN BURMA

AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022.  (AstraZeneca/Handout via REUTERS/File photo)

CLICK HERE TO GET THE FOX NEWS APP

The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.

Recommendations made by the human medicines committee will have to be formally approved by the European Commission.